» Articles » PMID: 36298493

Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina

Overview
Date 2022 Oct 27
PMID 36298493
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Quadrivalent cell-based influenza vaccines (QIVc) avoid egg-adaptive mutations and can be more effective than traditional quadrivalent egg-based influenza vaccines (QIVe). This analysis compared the cost-effectiveness of QIVc and QIVe in Argentinian populations < 65 years old from the payer and societal perspectives. Methods: A static decision tree model compared the costs and health benefits of vaccination with QIVc vs. QIVe using a one-year time horizon. The relative vaccine effectiveness of QIVc vs. QIVe was assumed to be 8.1% for children and 11.4% for adults. An alternative high egg-adaptation scenario was also assessed. Model inputs were sourced from Argentina or the international literature. Deterministic and probabilistic sensitivity analyses were performed. Results: Compared to QIVe, QIVc would prevent 17,857 general practitioner visits, 2418 complications, 816 hospitalizations, and 12 deaths per year. From the payers’ perspective, the incremental cost-effectiveness ratio per quality-adjusted life years gained was USD12,214 in the base case and USD2311 in the high egg-adaptation scenario. QIVc was cost-saving from the societal perspective in both scenarios. Conclusions: QIVc in Argentina would be cost-effective relative to QIVe. The potential health benefits and savings would be even higher in high egg-adaptation seasons.

Citing Articles

The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses.

Fisman D, Giglio N, Levin M, Nguyen V, Pelton S, Postma M Hum Vaccin Immunother. 2024; 20(1):2351675.

PMID: 38835218 PMC: 11155702. DOI: 10.1080/21645515.2024.2351675.


Fighting flu: novel CD8 T-cell targets are required for future influenza vaccines.

Leong S, Gras S, Grant E Clin Transl Immunology. 2024; 13(2):e1491.

PMID: 38362528 PMC: 10867544. DOI: 10.1002/cti2.1491.


Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Children: A Narrative Review.

Mould-Quevedo J, Pelton S, Nguyen V Vaccines (Basel). 2023; 11(10).

PMID: 37896996 PMC: 10610859. DOI: 10.3390/vaccines11101594.

References
1.
Bianculli P, Bellier L, Mangado I, Perez C, Mieres G, Lazarov L . Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis. Hum Vaccin Immunother. 2022; 18(5):2050653. PMC: 9225211. DOI: 10.1080/21645515.2022.2050653. View

2.
Marseille E, Larson B, Kazi D, Kahn J, Rosen S . Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015; 93(2):118-24. PMC: 4339959. DOI: 10.2471/BLT.14.138206. View

3.
Smeeth L, Thomas S, Hall A, Hubbard R, Farrington P, Vallance P . Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004; 351(25):2611-8. DOI: 10.1056/NEJMoa041747. View

4.
McElhaney J . The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine. 2005; 23 Suppl 1:S10-25. DOI: 10.1016/j.vaccine.2005.04.019. View

5.
Levine M, Martin E, Petrie J, Lauring A, Holiday C, Jefferson S . Antibodies Against Egg- and Cell-Grown Influenza A(H3N2) Viruses in Adults Hospitalized During the 2017-2018 Influenza Season. J Infect Dis. 2019; 219(12):1904-1912. PMC: 6534188. DOI: 10.1093/infdis/jiz049. View